Global GMP expansion Rephine recently appointed a new CEO Tim Hawkins and is intensifying global expansion across pharmaceutical, biotech and medical device sectors, signaling increased need for scalable quality assurance, GxP compliance, and cross-border audits to support growth.

Quality assurance leadership As a recognized gold standard in GxP consulting and audit services with over 25 years of experience, Rephine presents opportunities to upsell enhanced audits, advisory engagements, and integrated supply chain QA programs for mid to large biotech and device manufacturers.

Strategic partnerships Recent mergers and partnerships with Forum Auditorías and PQE Group, along with API and third-party auditing collaborations, indicate openness to expanded alliance-based service models that can be leveraged to cross-sell complementary compliance, risk assessments, and regulatory readiness offerings.

Tech-enabled services Rephine’s tech stack includes OneTrust, Oracle Cloud, DocuSign and analytics tools like Hotjar, suggesting opportunities to pitch expanded due diligence platforms, supplier qualification workflows, and digitized CAPA and audit reporting ecosystems for efficient GMP/GxP operations.

Mid-market growth focus With a headcount of 51-200 and revenue in the 10–25 million range, Rephine targets growing pharmaceutical and medical device players that require scalable QA programs; this presents sales potential for standardized modular services, training, and rapid-deployment audits tailored to mid-market companies expanding into new geographies.